%0 Journal Article
%T 钾竞争性酸阻断剂替戈拉生治疗酸相关疾病的研究进展<br>Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related Diseases
%A 卿岚
%A 白雪
%A 朱路阳
%A 赵媛
%A 延华
%J Advances in Clinical Medicine
%P 117-122
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1482189
%X 替戈拉生作为一种新型的钾竞争性酸阻断剂，能够高选择性的通过抑制H<sup>+</sup>/K<sup>+</sup> ATP酶，阻断H<sup>+</sup>-K<sup>+</sup>交换，有效减少胃酸分泌，同时能有效地克服质子泵抑制剂的不足，在治疗许多酸相关疾病中显示出良好的效果。本文对其药理学、临床应用研究进展及安全性加以总结。<br />
As a novel potassium-competitive acid blocker, tegoprazan can highly selectively block H<sup>+</sup>-K<sup>+</sup> exchange by inhibiting H<sup>+</sup>/K<sup>+</sup> ATPase, effectively reduce gastric acid secretion, and at the same time can effectively overcome the deficiencies of proton pump inhibitors, showing good results in the treatment of many acid-related diseases. This paper summarises the progress of its pharmacology, clinical application research and safety.
%K 替戈拉生&#65292
%K 质子泵抑制剂&#65292
%K 酸相关疾病<br>Tegoprazan
%K Proton Pump Inhibitors
%K Acid-Related Diseases
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=92969